Journey Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 23,508 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $5.19, for a total value of $122,006.52. Following the completion of the sale, the chief executive officer now owns 2,139,922 shares of the company's stock, valued at approximately $11,106,195.18. The trade was a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Claude Maraoui also recently made the following trade(s):
- On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The shares were sold at an average price of $5.13, for a total value of $93,094.11.
Journey Medical Trading Up 1.6 %
NASDAQ:DERM traded up $0.08 during trading hours on Friday, hitting $5.14. The company had a trading volume of 79,712 shares, compared to its average volume of 94,557. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The company has a 50-day moving average of $4.58 and a 200 day moving average of $5.08. The company has a market cap of $107.37 million, a P/E ratio of -5.47 and a beta of 0.96. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89.
Hedge Funds Weigh In On Journey Medical
A number of hedge funds have recently modified their holdings of DERM. Cetera Investment Advisers grew its holdings in shares of Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock worth $54,000 after purchasing an additional 2,478 shares during the period. Nwam LLC purchased a new position in shares of Journey Medical during the 3rd quarter worth $59,000. Kovitz Investment Group Partners LLC purchased a new position in shares of Journey Medical during the 3rd quarter worth $66,000. Dimensional Fund Advisors LP purchased a new position in shares of Journey Medical during the 4th quarter worth $80,000. Finally, Citadel Advisors LLC purchased a new position in shares of Journey Medical during the 4th quarter worth $174,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.
Journey Medical Company Profile
(
Get Free Report)
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
See Also
Before you consider Journey Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.
While Journey Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
